<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>National Heart and Lung Institute</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2DDFC3C4-BB32-4634-838E-3F27A9E5E670"><gtr:id>2DDFC3C4-BB32-4634-838E-3F27A9E5E670</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:surname>Sapey</gtr:surname><gtr:orcidId>0000-0003-3454-5482</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/977F0EC2-CBAD-4E2F-A4B8-68C5053E7C39"><gtr:id>977F0EC2-CBAD-4E2F-A4B8-68C5053E7C39</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Barnes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5831A630-7DB2-4F24-A6F3-8E19ABA445F9"><gtr:id>5831A630-7DB2-4F24-A6F3-8E19ABA445F9</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Stockley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D1C4F9E5-3357-4374-91EF-25BC04948545"><gtr:id>D1C4F9E5-3357-4374-91EF-25BC04948545</gtr:id><gtr:firstName>Louise</gtr:firstName><gtr:otherNames>E</gtr:otherNames><gtr:surname>Donnelly</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FE0D06D3-8E96-4D18-B531-03C370F0D6CB"><gtr:id>FE0D06D3-8E96-4D18-B531-03C370F0D6CB</gtr:id><gtr:firstName>Jadwiga</gtr:firstName><gtr:otherNames>Anna</gtr:otherNames><gtr:surname>Wedzicha</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/89D41141-59D3-401A-A3BC-0E21C4139A9C"><gtr:id>89D41141-59D3-401A-A3BC-0E21C4139A9C</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>H</gtr:otherNames><gtr:surname>Dockrell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F1102AAC-9185-4543-96F7-5DF867D916A5"><gtr:id>F1102AAC-9185-4543-96F7-5DF867D916A5</gtr:id><gtr:firstName>Gavin</gtr:firstName><gtr:otherNames>Christopher</gtr:otherNames><gtr:surname>Donaldson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EDB10808-C537-40F5-8043-E4D57C3F0B64"><gtr:id>EDB10808-C537-40F5-8043-E4D57C3F0B64</gtr:id><gtr:firstName>Moira</gtr:firstName><gtr:otherNames>Katherine</gtr:otherNames><gtr:surname>Whyte</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5E76EDD1-F861-48EA-BD1A-094873A21A1D"><gtr:id>5E76EDD1-F861-48EA-BD1A-094873A21A1D</gtr:id><gtr:firstName>Mike</gtr:firstName><gtr:surname>Yeadon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1001372"><gtr:id>4D477D3E-DFBB-4223-8B92-93DD58F22670</gtr:id><gtr:title>Mechanisms, impact and therapeutic targeting of bacterial colonisation in COPD</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001372</gtr:grantReference><gtr:abstractText>Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis and emphysema and is a very common cause of chronic disability and mortality in the UK. There is an underlying inflammation in the lungs of COPD patients which has so far proved very difficult to treat, so that there is a real need to find more effective treatments in the future. This will depend on better understanding the inflammation that occurs in the lungs of COPD patients, which is usually initiated by cigarette smoking. However, once the disease is established stopping smoking does not clear up the problem so we need to find new and more effective treatments. This grant application brings together some of the key centres for COPD research in the UK to explore a new idea. We know that bacteria (bugs) are present the lungs of COPD patients, unlike the lungs of smokers without COPD and non smokers which are sterile. The presence of these bacteria may drive inflammation, which then results in worsening of the disease and also increases the flare-ups, called exacerbations, which may lead to hospital admission. We believe that this is due to failure to remove bacteria from the lungs and therefore these bacteria grow and cause infections. We have evidence that cells that usually defend the lungs (called macrophages and neutrophils) do not eat up and clear the bacteria as they normally do. In addition, these cells fail to clear all the damaged cells from the lung making the inflammation even worse. We have found that these abnormalities can be explained by abnormal functioning of the macrophages and neutrophils and we have identified some of the mechanisms that have gone wrong. This means that we may be able to find treatments that can restore normal function to these cells so that they can sterilise the lung. This should mean that we can clean up the lung normally, which will lead to a reduction in flare-ups and halting the worsening of the disease. We plan to work closely with several pharmaceutical companies so that we can test any new treatments as soon as possible, so that we may be able to find treatments faster. We hope that this innovative research will therefore lead to new treatment approaches for COPD in the future.</gtr:abstractText><gtr:technicalSummary>Lower airway bacterial colonisation (LABC) affects approximately 50% of patients with COPD at all stages of disease and may be important in driving inflammation and impairing the resolution of inflammation. Our central hypothesis is that defective innate and/or adaptive immunity (impaired macrophage and neutrophil phagocytosis and killing of bacteria or humoral and cellular responses) results in failure to clear bacterial and apoptotic cells from the lower airways in smokers who develop COPD. We suggest that the resulting LABC (usually with Haemophilus influenzae, Streptococcus pneumoniae or Moraxella catarrhalis) drives a persistent inflammatory response, which is resistant to cues for resolution of inflammation. This collaborative application brings together major UK centres with expertise in COPD mechanisms, microbiology and immunology. We aim to explore the links between LABC, chronic inflammation and clinical outcomes, including exacerbation frequency and disease progression in COPD patients. We will determine the prevalence and impact of LABC in COPD patients at all stages of the disease and examine how this may reflect impaired innate immunity and resultant chronic inflammation and altered immune responses. We will elucidate the molecular mechanisms for reduced bacterial phagocytosis and killing reported in alveolar macrophages, monocyte-derived macrophages (MDM) and circulating neutrophils and for the impaired clearance of innate immune cells (efferocytosis) in order to identify novel therapeutic targets. Preliminary studies have identified abnormalities in microtubular stability and sphingosine-1-phosphate signalling in defective bacterial clearance by macrophages that are reversible in-vitro. Delays in macrophage apoptosis also reduce bacterial clearance and can be targeted therapeutically. We will investigate the effect of reducing LABC in COPD patients with antibiotic therapy (oral and inhaled) on inflammation and immune responses as proof-of-concept. Finally, we will perform PoC studies in COPD patients with drugs identified as correcting defective bacterial clearance in COPD cells, including microtubule stabilisers, sphingosine signalling inhibitors and apoptosis modulators. We will study carefully phenotyped COPD patients from existing well characterised cohorts and collaborate closely with other work packages of the consortium. We will interact closely with several industrial partners who have agreed to provide tool compounds, technological skills, data analyses and expertise in trial design. This proposal represents a series of focused and deliverable projects that, through collaborative scientific discovery, will act as a unique platform for therapeutic translation. We believe that exploring LABC and abnormal innate immunity will enhance understanding of disease mechanisms and identify new therapeutic approaches and provide novel biomarkers for the assessment of new treatments.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1003002</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>COPD MAP: Workpackage 2</gtr:description><gtr:id>C2577812-FABC-4AB0-9F54-7C925CCAD7D6</gtr:id><gtr:impact>No publications yet, but several abstracts have been presented at national and international meetings.

ERJ, September 2013, Volume 42, supplement 57
P629 Relationship between monocyte-derived macrophage phagocytosis and airway inflammation in stable COPD
R. Singh, K. Chana, K. Such, A. Patel, A. Mackay, D. Garcha, G. Donaldson, P. Barnes, J. Wedzicha, L. Donnelly

P2172 Concordance between airway inflammation and health status in COPD patients with bacterial colonisation
R. Singh, A. Mackay, A. Patel, B. Kowlessar, D. Garcha, S. Brill, R. Sapsford, L. Donnelly, P. Barnes, G. Donaldson, J. Wedzicha

3301 The species-specific inflammatory response of colonising bacteria in stable COPD
R. Singh, A. Patel, A. Mackay, D. Garcha, B. Kowlessar, S. Brill, R. Sapsford, L. Donnelly, P. Barnes, G. Donaldson, J. Wedzicha

P 3869 Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD
M. Bewley, K. Chana, R. Budd, R. Singh, D. Singh, W. Wedzicha, D. Dockrell, M. Whyte, P. J. Barnes, L. Donnelly

P3872 Increased susceptibility of M2 monocyte-derived macrophages from COPD patients to oxidative stress
K. Such, R. Singh, J. Wedzicha, P. Barnes, L. Donnelly

Am J Respir Clin Care Med 2014, volume 189

Sputum Color And The Detection Of Colonizing Bacteria By Quantitative PCR In Stable COPD
Richa Singh, , Alexander J. Mackay, Anant R.C. Patel, Davinder S. Garcha, Simon E. Brill, Louise E. Donnelly, Peter J. Barnes, Gavin C. Donaldson, Jadwiga A. Wedzicha: A1017

Alveolar Macrophages From Patients With COPD Have A Defect In Opsonic Phagocytosis Of
Streptococcus Pneumoniae
M. Bewley, R. Budd, D. Singh, P. J. Barnes, L. E. Donnelly, D. H. Dockrell, M. K.B. Whyte, Medical Research Council COPD
MAP Consortium A1011

Alveolar Macrophages During COPD Demonstrate Reduced Apoptosis-Associated Bacterial Killing And
Reduced Mitochondrial Reactive Oxygen Species-Dependent Killing
M. Bewley, R. Budd, D. Singh, P. J. Barnes, L. E. Donnelly, M. K.B. Whyte, D. H. Dockrell, Medical Research Council COPD
MAP Consortium A 2862

ERJ, September 2014, Volume 44, Supplement 58

P1479 Oxidative stress drives defective efferocytosis in COPD M2-like macrophages
K. Belchamber, R. Singh, J. Wedzicha, M. Whyte, P. Barnes, L. Donnelly

2957 TNFa release by monocyte-derived macrophages at stable and exacerbation states in COPD
R. Singh, K. Belchamber, A. Mackay, B. Kowlessar, J. Allinson, S. Brill, G. Donaldson, P. Barnes, J. Wedzicha, L. Donnelly

3399 Relationship of monocyte-derived macrophage phagocytosis to exacerbation susceptibility in stable COPD
R. Singh, K. Belchamber, A. Mackay, B. Kowlessar, J. Allinson, S. Brill, G. Donaldson, P. Barnes, J. Wedzicha, L. Donnelly</gtr:impact><gtr:partnerContribution>We have shared and harmonised experimental protocols, trained post-doctoral scientists and technicians and exchanged clinical samples between the centres.
Industrial collaborators have provided analytical tools and expertise, including MSD protein analysis, microbiome and data analysis.</gtr:partnerContribution><gtr:piContribution>We have established a very successful collaboration with University College London (Prof Wisia Wedzicha, Dr Gavin Donaldson), University of Sheffield (Prof Moira Whyte, Dr David Dockrell) and University of Birmingham (Prof Robert Stockley, Dr Liz Sapey) to study bacterial colonisation of the lower airways in patients with COPD.
Professor Wedzicha's group has now successfully relocated to Imperial and has been incorporated into Airway Disease Section.
We have developed close collaborations with Pfizer (Dr Iain Kilty, Dr Christelle Perros-Huguet), GSK (Dr Ruth Tal-Singer, Dr Edith Hessell) and MedImmune (Dr Matt Robinson).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>COPD MAP: Workpackage 2</gtr:description><gtr:id>B717F456-8515-47F3-B27B-D4286D19DF94</gtr:id><gtr:impact>No publications yet, but several abstracts have been presented at national and international meetings.

ERJ, September 2013, Volume 42, supplement 57
P629 Relationship between monocyte-derived macrophage phagocytosis and airway inflammation in stable COPD
R. Singh, K. Chana, K. Such, A. Patel, A. Mackay, D. Garcha, G. Donaldson, P. Barnes, J. Wedzicha, L. Donnelly

P2172 Concordance between airway inflammation and health status in COPD patients with bacterial colonisation
R. Singh, A. Mackay, A. Patel, B. Kowlessar, D. Garcha, S. Brill, R. Sapsford, L. Donnelly, P. Barnes, G. Donaldson, J. Wedzicha

3301 The species-specific inflammatory response of colonising bacteria in stable COPD
R. Singh, A. Patel, A. Mackay, D. Garcha, B. Kowlessar, S. Brill, R. Sapsford, L. Donnelly, P. Barnes, G. Donaldson, J. Wedzicha

P 3869 Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD
M. Bewley, K. Chana, R. Budd, R. Singh, D. Singh, W. Wedzicha, D. Dockrell, M. Whyte, P. J. Barnes, L. Donnelly

P3872 Increased susceptibility of M2 monocyte-derived macrophages from COPD patients to oxidative stress
K. Such, R. Singh, J. Wedzicha, P. Barnes, L. Donnelly

Am J Respir Clin Care Med 2014, volume 189

Sputum Color And The Detection Of Colonizing Bacteria By Quantitative PCR In Stable COPD
Richa Singh, , Alexander J. Mackay, Anant R.C. Patel, Davinder S. Garcha, Simon E. Brill, Louise E. Donnelly, Peter J. Barnes, Gavin C. Donaldson, Jadwiga A. Wedzicha: A1017

Alveolar Macrophages From Patients With COPD Have A Defect In Opsonic Phagocytosis Of
Streptococcus Pneumoniae
M. Bewley, R. Budd, D. Singh, P. J. Barnes, L. E. Donnelly, D. H. Dockrell, M. K.B. Whyte, Medical Research Council COPD
MAP Consortium A1011

Alveolar Macrophages During COPD Demonstrate Reduced Apoptosis-Associated Bacterial Killing And
Reduced Mitochondrial Reactive Oxygen Species-Dependent Killing
M. Bewley, R. Budd, D. Singh, P. J. Barnes, L. E. Donnelly, M. K.B. Whyte, D. H. Dockrell, Medical Research Council COPD
MAP Consortium A 2862

ERJ, September 2014, Volume 44, Supplement 58

P1479 Oxidative stress drives defective efferocytosis in COPD M2-like macrophages
K. Belchamber, R. Singh, J. Wedzicha, M. Whyte, P. Barnes, L. Donnelly

2957 TNFa release by monocyte-derived macrophages at stable and exacerbation states in COPD
R. Singh, K. Belchamber, A. Mackay, B. Kowlessar, J. Allinson, S. Brill, G. Donaldson, P. Barnes, J. Wedzicha, L. Donnelly

3399 Relationship of monocyte-derived macrophage phagocytosis to exacerbation susceptibility in stable COPD
R. Singh, K. Belchamber, A. Mackay, B. Kowlessar, J. Allinson, S. Brill, G. Donaldson, P. Barnes, J. Wedzicha, L. Donnelly</gtr:impact><gtr:partnerContribution>We have shared and harmonised experimental protocols, trained post-doctoral scientists and technicians and exchanged clinical samples between the centres.
Industrial collaborators have provided analytical tools and expertise, including MSD protein analysis, microbiome and data analysis.</gtr:partnerContribution><gtr:piContribution>We have established a very successful collaboration with University College London (Prof Wisia Wedzicha, Dr Gavin Donaldson), University of Sheffield (Prof Moira Whyte, Dr David Dockrell) and University of Birmingham (Prof Robert Stockley, Dr Liz Sapey) to study bacterial colonisation of the lower airways in patients with COPD.
Professor Wedzicha's group has now successfully relocated to Imperial and has been incorporated into Airway Disease Section.
We have developed close collaborations with Pfizer (Dr Iain Kilty, Dr Christelle Perros-Huguet), GSK (Dr Ruth Tal-Singer, Dr Edith Hessell) and MedImmune (Dr Matt Robinson).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>COPD MAP: Workpackage 2</gtr:description><gtr:id>1819B3BD-C5FB-462F-A3F9-0F8659C63700</gtr:id><gtr:impact>No publications yet, but several abstracts have been presented at national and international meetings.

ERJ, September 2013, Volume 42, supplement 57
P629 Relationship between monocyte-derived macrophage phagocytosis and airway inflammation in stable COPD
R. Singh, K. Chana, K. Such, A. Patel, A. Mackay, D. Garcha, G. Donaldson, P. Barnes, J. Wedzicha, L. Donnelly

P2172 Concordance between airway inflammation and health status in COPD patients with bacterial colonisation
R. Singh, A. Mackay, A. Patel, B. Kowlessar, D. Garcha, S. Brill, R. Sapsford, L. Donnelly, P. Barnes, G. Donaldson, J. Wedzicha

3301 The species-specific inflammatory response of colonising bacteria in stable COPD
R. Singh, A. Patel, A. Mackay, D. Garcha, B. Kowlessar, S. Brill, R. Sapsford, L. Donnelly, P. Barnes, G. Donaldson, J. Wedzicha

P 3869 Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD
M. Bewley, K. Chana, R. Budd, R. Singh, D. Singh, W. Wedzicha, D. Dockrell, M. Whyte, P. J. Barnes, L. Donnelly

P3872 Increased susceptibility of M2 monocyte-derived macrophages from COPD patients to oxidative stress
K. Such, R. Singh, J. Wedzicha, P. Barnes, L. Donnelly

Am J Respir Clin Care Med 2014, volume 189

Sputum Color And The Detection Of Colonizing Bacteria By Quantitative PCR In Stable COPD
Richa Singh, , Alexander J. Mackay, Anant R.C. Patel, Davinder S. Garcha, Simon E. Brill, Louise E. Donnelly, Peter J. Barnes, Gavin C. Donaldson, Jadwiga A. Wedzicha: A1017

Alveolar Macrophages From Patients With COPD Have A Defect In Opsonic Phagocytosis Of
Streptococcus Pneumoniae
M. Bewley, R. Budd, D. Singh, P. J. Barnes, L. E. Donnelly, D. H. Dockrell, M. K.B. Whyte, Medical Research Council COPD
MAP Consortium A1011

Alveolar Macrophages During COPD Demonstrate Reduced Apoptosis-Associated Bacterial Killing And
Reduced Mitochondrial Reactive Oxygen Species-Dependent Killing
M. Bewley, R. Budd, D. Singh, P. J. Barnes, L. E. Donnelly, M. K.B. Whyte, D. H. Dockrell, Medical Research Council COPD
MAP Consortium A 2862

ERJ, September 2014, Volume 44, Supplement 58

P1479 Oxidative stress drives defective efferocytosis in COPD M2-like macrophages
K. Belchamber, R. Singh, J. Wedzicha, M. Whyte, P. Barnes, L. Donnelly

2957 TNFa release by monocyte-derived macrophages at stable and exacerbation states in COPD
R. Singh, K. Belchamber, A. Mackay, B. Kowlessar, J. Allinson, S. Brill, G. Donaldson, P. Barnes, J. Wedzicha, L. Donnelly

3399 Relationship of monocyte-derived macrophage phagocytosis to exacerbation susceptibility in stable COPD
R. Singh, K. Belchamber, A. Mackay, B. Kowlessar, J. Allinson, S. Brill, G. Donaldson, P. Barnes, J. Wedzicha, L. Donnelly</gtr:impact><gtr:partnerContribution>We have shared and harmonised experimental protocols, trained post-doctoral scientists and technicians and exchanged clinical samples between the centres.
Industrial collaborators have provided analytical tools and expertise, including MSD protein analysis, microbiome and data analysis.</gtr:partnerContribution><gtr:piContribution>We have established a very successful collaboration with University College London (Prof Wisia Wedzicha, Dr Gavin Donaldson), University of Sheffield (Prof Moira Whyte, Dr David Dockrell) and University of Birmingham (Prof Robert Stockley, Dr Liz Sapey) to study bacterial colonisation of the lower airways in patients with COPD.
Professor Wedzicha's group has now successfully relocated to Imperial and has been incorporated into Airway Disease Section.
We have developed close collaborations with Pfizer (Dr Iain Kilty, Dr Christelle Perros-Huguet), GSK (Dr Ruth Tal-Singer, Dr Edith Hessell) and MedImmune (Dr Matt Robinson).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Bring Your Child to Work Day at NHLI</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>16E9E44F-C77C-480E-9C69-1FEC6540C9AE</gtr:id><gtr:impact>Described in the following website:

http://www1.imperial.ac.uk/nhli/aboutus/child_to_work_day/ - 


Great interest in the children. Encouraged discussion of life-work balance between colleagues with children.
Interest to run similar programmes in local schools.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www1.imperial.ac.uk/nhli/aboutus/child_to_work_day/</gtr:url><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient and volunteer engagement</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C9735BEA-6B3E-412B-8151-F9F21BEB9825</gtr:id><gtr:impact>2 Open Days that invited all patients and normal control subjects to present our research and to get feedback and answer questions from study participants. Very positive feedback from the meeting and more are planned.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Heart &amp; Lung Shop</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F8DB8A6C-33F5-454D-AB77-688190B720EA</gtr:id><gtr:impact>Details provided on the following website:
http://www1.imperial.ac.uk/nhli/public_engagement/the_curious_act/heart_and_lung_repair_shops/



High level of interest from the public in participating in clinical trials and in receiving more information. We plan to continue these popular events in the future.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www1.imperial.ac.uk/nhli/public_engagement/the_curious_act/heart_and_lung_repair_shops/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hakathon for developing new devices for respiratory diseases</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1975B6E5-71F5-4106-B53C-654D1B92081A</gtr:id><gtr:impact>Interactive meeting at Imperial College and beamed to MIT (Cambridge, USA) to discuss new monitoring devices for patients with lung diseases such as COPD. Involved discussion about patients needs with engineers scientists and doctors. Received a lot of national publicity.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/eventssummary/event_7-9-2015-17-28-1</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Imperial Festival 2012</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A96910A1-EAAE-4A93-8044-7F0EB82D8089</gtr:id><gtr:impact>Described in the following website:
http://www3.imperial.ac.uk/festival/previousfestivals/imperialfestival2012

Increased public awareness about lung disease, particularly COPD. Engagement of children with a locally devised COPD board game.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www3.imperial.ac.uk/festival/previousfestivals/imperialfestival2012</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory Placement for final year school pupils</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>239C9C68-105C-4FBE-BF35-ED6DA01EC4C5</gtr:id><gtr:impact>2 week placement visit to different laboratories and hospital laboratories.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Global guidelines for COPD</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>07A9802F-9B88-4ADF-8B68-DBC968D080C2</gtr:id><gtr:impact>Influence on management of COPD worldwide</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.goldcopd.com/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52670A6E-D5D5-4F3B-AEDF-57E48F86952E"><gtr:id>52670A6E-D5D5-4F3B-AEDF-57E48F86952E</gtr:id><gtr:title>Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53F136D0-5208-40D8-BEC5-8D581751A956"><gtr:id>53F136D0-5208-40D8-BEC5-8D581751A956</gtr:id><gtr:title>Beta-blockers in COPD: time for reappraisal.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/15ac1ceac61efae3b5e2b60458b2522f"><gtr:id>15ac1ceac61efae3b5e2b60458b2522f</gtr:id><gtr:otherNames>Lipworth B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF813DF8-3BEF-4993-AD91-DD74E2673038"><gtr:id>AF813DF8-3BEF-4993-AD91-DD74E2673038</gtr:id><gtr:title>Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bdfb66698bf12de7c9639a895d0cb7e8"><gtr:id>bdfb66698bf12de7c9639a895d0cb7e8</gtr:id><gtr:otherNames>Law M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7FF7AE3-CBC7-40AD-80C4-160D0B212C85"><gtr:id>D7FF7AE3-CBC7-40AD-80C4-160D0B212C85</gtr:id><gtr:title>Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ddd38ca11db008642251078e0d028a02"><gtr:id>ddd38ca11db008642251078e0d028a02</gtr:id><gtr:otherNames>Singh R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/37CEA894-D64F-4824-8406-455645390864"><gtr:id>37CEA894-D64F-4824-8406-455645390864</gtr:id><gtr:title>Eosinophils as Biomarkers of Chronic Obstructive Pulmonary Disease Exacerbation Risk. Maybe Just for Some?</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30A19CB4-D9C1-4846-81E8-181DAE4EA390"><gtr:id>30A19CB4-D9C1-4846-81E8-181DAE4EA390</gtr:id><gtr:title>Factors associated with change in exacerbation frequency in COPD.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e262baaf0838444302933c5ad7ede29"><gtr:id>8e262baaf0838444302933c5ad7ede29</gtr:id><gtr:otherNames>Donaldson GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E283F1AD-8B80-4E87-A25B-E82699C7F241"><gtr:id>E283F1AD-8B80-4E87-A25B-E82699C7F241</gtr:id><gtr:title>Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT).</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8499eff348b9c9cc90ed8296201bbccb"><gtr:id>8499eff348b9c9cc90ed8296201bbccb</gtr:id><gtr:otherNames>Mackay AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FE8ECB20-2022-4809-9C3B-D941A266FF57"><gtr:id>FE8ECB20-2022-4809-9C3B-D941A266FF57</gtr:id><gtr:title>Physical activity and exercise capacity in patients with moderate COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f8dffe8853ae5656cd9e496c0c8add70"><gtr:id>f8dffe8853ae5656cd9e496c0c8add70</gtr:id><gtr:otherNames>Alahmari AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87CA4715-099E-46C8-99C3-C660F9FE6114"><gtr:id>87CA4715-099E-46C8-99C3-C660F9FE6114</gtr:id><gtr:title>Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5b58adb64320d9f920280ec466c001d1"><gtr:id>5b58adb64320d9f920280ec466c001d1</gtr:id><gtr:otherNames>Roche N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6EF53A6F-CAD2-4027-A9AC-28AAA5A76366"><gtr:id>6EF53A6F-CAD2-4027-A9AC-28AAA5A76366</gtr:id><gtr:title>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fce180d130b001297302c71100206dd6"><gtr:id>fce180d130b001297302c71100206dd6</gtr:id><gtr:otherNames>Vogelmeier CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B6178E9E-31B9-4AB0-9F3A-F4D0FFDF912F"><gtr:id>B6178E9E-31B9-4AB0-9F3A-F4D0FFDF912F</gtr:id><gtr:title>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report.</gtr:title><gtr:parentPublicationTitle>Archivos de bronconeumologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fce180d130b001297302c71100206dd6"><gtr:id>fce180d130b001297302c71100206dd6</gtr:id><gtr:otherNames>Vogelmeier CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-2896</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/926138D2-C8EE-4197-8CE2-207D81BA6B93"><gtr:id>926138D2-C8EE-4197-8CE2-207D81BA6B93</gtr:id><gtr:title>Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients.</gtr:title><gtr:parentPublicationTitle>BMC pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2f4691d4afeba46a9833b90572523d93"><gtr:id>2f4691d4afeba46a9833b90572523d93</gtr:id><gtr:otherNames>Lawrence PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2466</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B39CA37C-397C-440E-B5BC-D3FC0A5A11B7"><gtr:id>B39CA37C-397C-440E-B5BC-D3FC0A5A11B7</gtr:id><gtr:title>Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6307dbd9b4ae066c0baaf12c18506016"><gtr:id>6307dbd9b4ae066c0baaf12c18506016</gtr:id><gtr:otherNames>Bewley MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54B5F7F4-CBCF-4AED-A473-50CF6E99A868"><gtr:id>54B5F7F4-CBCF-4AED-A473-50CF6E99A868</gtr:id><gtr:title>Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6307dbd9b4ae066c0baaf12c18506016"><gtr:id>6307dbd9b4ae066c0baaf12c18506016</gtr:id><gtr:otherNames>Bewley MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F55778B4-2419-4ACD-BEE4-A8BA5249575B"><gtr:id>F55778B4-2419-4ACD-BEE4-A8BA5249575B</gtr:id><gtr:title>Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44262b2dce43af0a517a8d9359049458"><gtr:id>44262b2dce43af0a517a8d9359049458</gtr:id><gtr:otherNames>Rodriguez-Roisin R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/22049D7E-C589-4FAB-94B1-516CCF12EA02"><gtr:id>22049D7E-C589-4FAB-94B1-516CCF12EA02</gtr:id><gtr:title>Roflumilast: a review of its use in the treatment of COPD.</gtr:title><gtr:parentPublicationTitle>International journal of chronic obstructive pulmonary disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1176-9106</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F0A1A2C6-5D86-45C6-98B9-F5D271483EF2"><gtr:id>F0A1A2C6-5D86-45C6-98B9-F5D271483EF2</gtr:id><gtr:title>Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.</gtr:title><gtr:parentPublicationTitle>COPD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1541-2563</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/07D888A4-13E1-41DF-AE5B-91AF70D781FF"><gtr:id>07D888A4-13E1-41DF-AE5B-91AF70D781FF</gtr:id><gtr:title>The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1ffe59fc47e844902206e70ad18bb1b3"><gtr:id>1ffe59fc47e844902206e70ad18bb1b3</gtr:id><gtr:otherNames>Allinson JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53DBA40E-9F80-4B0B-846A-3D673021406E"><gtr:id>53DBA40E-9F80-4B0B-846A-3D673021406E</gtr:id><gtr:title>Predicting In-Hospital Treatment Failure (= 7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids.</gtr:title><gtr:parentPublicationTitle>COPD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f73cd47ec8e43d9d3734666f444e5219"><gtr:id>f73cd47ec8e43d9d3734666f444e5219</gtr:id><gtr:otherNames>Crisafulli E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1541-2563</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/08C98F2E-F018-4FBA-8504-6D0F915C4D44"><gtr:id>08C98F2E-F018-4FBA-8504-6D0F915C4D44</gtr:id><gtr:title>Blood eosinophils and inhaled corticosteroid/long-acting ?-2 agonist efficacy in COPD.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/196260af99aec105dadcc0b8ace298d9"><gtr:id>196260af99aec105dadcc0b8ace298d9</gtr:id><gtr:otherNames>Pavord ID</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FFAAE71A-70DF-4F8B-8093-0BC1FD208FE4"><gtr:id>FFAAE71A-70DF-4F8B-8093-0BC1FD208FE4</gtr:id><gtr:title>Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease &amp;quot;Super Exacerbators&amp;quot;.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2AC0C83-A974-46BD-A4BB-B73708DE6BA5"><gtr:id>C2AC0C83-A974-46BD-A4BB-B73708DE6BA5</gtr:id><gtr:title>How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11b830c588d08eee3ff3f298e8cf1e4c"><gtr:id>11b830c588d08eee3ff3f298e8cf1e4c</gtr:id><gtr:otherNames>Beeh KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/79E82E24-AFA4-4BBF-B191-3284DC0B4549"><gtr:id>79E82E24-AFA4-4BBF-B191-3284DC0B4549</gtr:id><gtr:title>Randomized Double-blind Controlled Trial of Roflumilast at Acute Exacerbations of COPD.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8499eff348b9c9cc90ed8296201bbccb"><gtr:id>8499eff348b9c9cc90ed8296201bbccb</gtr:id><gtr:otherNames>Mackay AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C90B74DC-A4B4-466A-AAE2-7F285DC12FA1"><gtr:id>C90B74DC-A4B4-466A-AAE2-7F285DC12FA1</gtr:id><gtr:title>Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.</gtr:title><gtr:parentPublicationTitle>International journal of chronic obstructive pulmonary disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1176-9106</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3F33AFB2-1DB8-4B23-8034-2F0D7D5828D8"><gtr:id>3F33AFB2-1DB8-4B23-8034-2F0D7D5828D8</gtr:id><gtr:title>First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.</gtr:title><gtr:parentPublicationTitle>NPJ primary care respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/343b1902ba6205692a14f688cda3d893"><gtr:id>343b1902ba6205692a14f688cda3d893</gtr:id><gtr:otherNames>Price D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2055-1010</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/271E52D1-4DF0-41B8-8A00-49A056B31CD8"><gtr:id>271E52D1-4DF0-41B8-8A00-49A056B31CD8</gtr:id><gtr:title>The role of complement activation in COPD exacerbation recovery.</gtr:title><gtr:parentPublicationTitle>ERJ open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/298dc366eae0b645b4c9eae351377e4e"><gtr:id>298dc366eae0b645b4c9eae351377e4e</gtr:id><gtr:otherNames>Westwood JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2312-0541</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001372</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>